There is increasing evidence that HOX homeobox genes play a role in leukemogenesis. Recent studies have demonstrated that enforced co-expression of HOXA9 and MEIS1 in murine marrow leads to rapid development of myeloid leukemia, and that these proteins exhibit cooperative DNA binding. However, it is unclear whether co-activation of HOXA9 and MEIS genes is a common occurrence in human leukemias. We surveyed expression of HOXA9 and MEIS1 in 24 leukemic cell lines and 80 patient samples, using RNase protection analyses and immunohistochemistry. We demonstrate that the expression of HOXA9 and MEIS1 in leukemia cells is uniquely myeloid, and that these genes are commonly co-expressed in myeloid cell lines and in samples of acute myelogenous leukemia (AML) of all subtypes except in promyelocytic leukemia. While HOXA9 is expressed in most cases of chronic myelogenous leukemia, MEIS1 is weakly expressed or not at all. Immunohistochemical staining of selected AML samples showed moderate to high levels of HOXA9 protein, primarily cytoplasmic, in leukemic myeloblasts, with weaker and primarily nuclear staining for MEIS1. These data support the concept that co-activation of HOXA9 and MEIS1 is a common event in AML, and may represent a common pathway of many different oncogenic mutations.
Introduction
There is increasing evidence that DNA-binding proteins encoded by the HOX family of homeobox genes play a role in leukemic transformation. Several HOXA and HOXB genes are expressed in myeloid leukemias, [1] [2] [3] with HOXC genes expressed predominantly in lymphoid malignancies. 4, 5 Evidence that mutations of HOX genes occur in human leukemias comes from characterization of the t(7;11) translocation, seen in rare cases of acute myelogenous leukemia (AML), 6 and which results in the fusion of the HOXA9 gene with a nucleoporin gene. 7, 8 However, these studies do not establish a causal role for HOX genes in leukemic transformation. In this regard, the enforced expression of HOXB8 together with IL-3 in murine marrow cells leads to myeloid leukemia; 9 similarly, over-expression of Hoxa-10 can induce myeloid leukemia after a long latency period. 10 These findings suggest that misexpression of HOX genes can contribute to transformation but additional genetic events are required.
Support for a role of HOX genes in spontaneous leukemias arose from studies of the BXH-2 mice, which develop a high incidence of myeloid leukemia. A novel non-HOX homeobox gene, Meis1, is up-regulated as a consequence of retroviral integration in 15% of leukemias arising in BXH-2 mice. 11 Subsequent studies have revealed frequent activating insertions of the Hoxa-9 or Hoxa-7 genes together with the Meis1 gene in these leukemias. 12 Recent work has shown that the engineered co-expression of the Hoxa-9 and Meis1 genes in murine hematopoietic cells leads to rapid development of AML, 13 indicating a synergy between the two genes and suggesting that co-activation of these genes is sufficient for transformation.
We have recently demonstrated that HOXA9 and HOXA10 proteins can interact with the MEIS1 protein and stabilize MEIS1-DNA interactions on consensus binding sites.
14 These data support the notion that the leukemogenicity of the HOXA9 and MEIS1 genes is related to the concerted actions of their protein products on gene targets. A major question remains whether co-activation of these genes occurs in human leukemias. In this study we surveyed expression patterns of both genes in a large panel of human cell lines and primary samples of leukemia, and observed frequent lineage-specific co-expression of these two genes in AML.
Materials and methods

Leukemic cell lines and patient samples
Twenty-four human leukemic cell lines were studied, as outlined in Figure 1 . All lines were maintained in media as previously described. 15 Cryopreserved cell samples from 80 patients, gathered from six different centers, with various forms of myeloid and lymphoid leukemias and myelodysplasia were studied and subclassified according to the FrenchAmerican-British (FAB) nomenclature. The original samples contained a range of 30-100 × 10 6 cells each and in some cases were over 10 years old. In all cases, leukocytes were isolated by either a buffy-coat preparation or Ficoll-Hypaque density centrifugation before freezing in liquid nitrogen. Cryopreserved samples were thawed quickly by shaking in a 37°C water bath, diluted in warm RPMI with 10% fetal calf serum, pelleted, washed with medium and repelleted for RNA isolation by the guanidinium thiocyanate/acid phenol method. 16 Samples of normal marrow and peripheral blood leukocytes were prepared as previously described. 4 
RNase protection analysis
Templates were constructed by subcloning a 378-nt fragment of the HOXA9 cDNA, extending from amino acid 147 to the end of the coding cDNA at amino acid 270; and a 394 nt fragment of MEISI, extending from amino acid 287 to the end of the MEISIa cDNA, into the sk+ Bluescript vector using standard procedures. Total RNA (25-50 g/samples) from individual specimens was subjected to separate RNase protection assays for each gene, following previously published methods. 17 As an internal control for loading, a probe protecting an 83-nt fragment of glyceraldehyde 3-phosphate Expression of HOXA9 and MEIS1 in human leukemic cell lines. Total RNA was isolated from 24 immortalized human leukemic lines and subjected to separate RNase protection assays for HOXA9 (top panel) and MEIS1 (middle panel), using a probe for glyceraldehyde-3 phosphate dehydrogenase (G3PD, lower panel) as an internal control for RNA loading, as described in Materials and methods. A clear signal for HOXA9 and MEIS1 is seen in 6/8 and 4/7 myeloid cell lines, respectively, with isolated expression of HOXA9 in the MB02 and M70E lines, and isolated expression of MEIS1 in a few of the non-myeloid lines. The signals for G3PD represent short exposure times to more clearly demonstrate relative loading. dehydrogenase (G3PD) was included in each assay. RNA isolated from the KG-1 cell line was used as a positive control.
For patient samples, autoradiographs of RNase protection experiments were developed for 1 day for visualization of the G3PD signal and for 3-7 days for HOXA9 and MEIS1. Densitometric scanning of the RNase protection bands for HOXA9 and MEIS1 were performed and normalized to the G3PD band from the same gel (to correct for differences in loading), and then normalized between gels by comparing the signals for KG-1 cell RNA, as previously described. 1 Expression levels for both genes were then assigned a value of 0 to 4+.
Immunohistochemical localization of homeobox proteins
Previously unstained blood or bone marrow smears from selected samples of acute leukemia were fixed in 4% formaldehyde (freshly prepared from paraformaldehyde) in PBS for 24 h. For immunohistochemical localization, HOXA9 was detected with affinity-purified chicken antibodies followed by biotin-conjugated anti-chicken rabbit IgG FAB fragment (Jackson Immunochemicals, West Grove, PA, USA), followed by detection with ABC alkaline phosphatase (Vector Labs, Burlingame, CA, USA). MEIS1 was detected with affinity-purified guinea pig antibodies followed by biotin-conjugated antiguinea pig rabbit IgG FAB fragment followed by detection with ABC alkaline phosphatase. Specimens were counterstained with methyl green to visualize nuclei. Slides were mounted with Vectashield (Vector Labs), photographed and scanned, and images were assembled and labeled on a MacIntosh G3 computer with Adobe Photoshop. Protein expression levels were scored on an arbitrary scale of +1 to +4.
Results
Myeloid-specific expression of HOXA9 expression in leukemic cell lines
Total RNA was isolated from 24 human leukemic cell lines and analyzed for HOXA9 expression by RNase protection analysis. As shown in Figure 1 , HOXA9 was expressed exclusively in myelomonocytic cells, with the sole exception of the bi-phenotypic MBO2 erythroid/myeloid line and the M70E megakaryocytic line. Two of eight myeloid cell lines tested, TMM and HL60, had no detectable HOXA9 message. The lymphoid lines studied were uniformly negative for expression of this gene. This pattern of expression is virtually identical to the pattern previously observed for the neighboring HOXA10 gene.
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MEIS1 expression in leukemic cell lines
When the myeloid cell lines were assayed for MEIS1 expression by RNase protection analysis, transcripts were detected in all but one (THP-1) of the lines which showed HOXA9 expression ( Figure 1 ). Thus in four of seven myeloid cell lines, there was co-expression of both genes. However MEIS1 also showed detectable expression in a few B cell (SU, U266), T cell (MOLT4), erythroid (HEL, K562) and megakaryocytic (Dami) cell lines which did not express HOXA9.
Myeloid-specific expression of HOXA9 and MEIS1 in primary samples of human leukemia
Total RNA from 80 archival samples representing a variety of subtypes of myeloid and lymphoid leukemias was subjected to RNase protection assays for expression of HOXA9 and MEIS1. Although for the majority of cases both genes were assayed, material limitations resulted in assay of only one gene for a few cases. Representative data is depicted in Figure  2 , and the findings for all the samples are summarized in
Figure 2
Co-expression of HOXA9 and MEIS1 in primary samples of myeloid leukemias. RNase protection assays were performed on total RNA isolated from frozen bone marrow samples, as described in Figure 1 . Separate analyses were performed for HOXA9 and MEIS1 using nonhomeobox containing probes to ensure specificity. Gels were autoradiographed for 3-5 days for HOXA9 and MEIS1 or overnight for G3PD, respectively. Both genes are clearly co-expressed in most cases of FAB-M0, -M1, -M2 and -M4. However, the samples of FAB-M3 are uniformly negative for the expression of both genes. HOXA9 is expressed in all of the secondary AMLs tested, while MEIS1 expression was detected in two of three cases (trace amount seen in sample No. 17 on longer exposure). While HOXA9 is expressed in nearly all cases of MDS and chronic phase CML, the expression of MEIS1 is much weaker in those samples. Neither gene is strongly expressed in blast crisis of CML (data not shown). Expression of both genes is uniformly negative in B and T cell leukemias. The smearing seen in most lanes is most likely RNA degradation related to prolonged storage of archival samples. Table 1 . The expression of HOXA9 in these primary samples was essentially identical to that seen in our previous survey for HOXA10 expression, using many of the same samples.
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HOXA9 shows an exclusively myeloid-specific expression with rare exceptions, namely one of three cases of T cell leukemia involving the t(10:14) translocation. Of the five cases of mixed-lineage leukemias involving translocations of 11q one was positive and two showed barely detectable expression (Table 1) . Otherwise, HOXA9 message was uniformly undetectable in 18 samples of B cell acute lymphocytic leukemias and one case of chronic lymphocytic leukemia (data not shown). When AML samples were broken down by FAB classification, it was of interest to note that HOXA9 message was not found in any of five promyelocytic leukemic samples (Table 1 and Figure 2 ). Otherwise HOXA9 was expressed in every case of FAB-M2 and FAB-M4 tested, all six cases of secondary AML, all eight cases of myelodysplasia (MDS), one case of an undifferentiated myeloproliferative disorder, and all four samples of stable-phase chronic myelogenous leukemia (Figure 2 and data not shown). Curiously, HOXA9 message was not seen in four of six samples of CML in blast crisis, including two samples of lymphoid blast crisis.
MEIS1 displayed a similar myeloid-restricted pattern of expression, with no detectable expression in any of 20 lymphoid samples (Figure 2 and data not shown). As with HOXA9 and HOXA10, 1 MEIS1 message was not seen in any of six Figure 2 . Bands for HOXA9 and MEISI were quantitated by densitometric scanning of autoradiographs, using an arbitrary scale from trace to +4. neg, no detectable expression; ND, not done; AML, acute myelogenous leukemia, 2°AML, secondary AML; RA, refractory anemia; RAEB, RA with excess blasts; RAEBIT, RA with excess blasts in transition; CMML, chronic myelogenous leukemia; CML-CP, chronic myelogenous leukemia in chronic phase; CML-AP, CML in acute phase; CML-BC, CML in blast crisis; ALL, acute lymphoblastic leukemia; AL, acute leukemia (mixed lineage involving 11q).
promyelocytic leukemia samples tested, but was expressed in 13 of 19 (68%) other AML samples tested ( Figure 2 and Table  1 ). MEIS1 was expressed in five of eight cases of myelodysplasia, although expression levels in some cases of myelodysplasia were weak. MEIS1 was expressed weakly or not at all in samples of CML, regardless of the stage of disease. HOXA9 and MEIS1 were frequently co-expressed in AML, and less often and less intensely in MDS and CML. In those cases of primary and secondary AML (excluding promyelocytic leukemia) for which both genes could be assayed in the same sample, 12 of 18 cases (67%) expressing HOXA9 also expressed MEIS1, and in no case studied was MEIS1 expression detected in the absence of HOXA9.
Expression of HOXA9 and MEIS1 RNA in normal blood cells
Total RNA was isolated from normal unfractionated bone marrow, and purified populations of peripheral blood granulocytes, monocytes and lymphocytes and analyzed by RNase protection. Both HOXA9 and MEIS1 were detectably expressed in normal marrow but not any of the mature cell fractions from the peripheral blood (data not shown), results similar to those reported for HOXA10. 1 The findings for HOXA9 are also consistent with previous studies showing that HOXA9 expression is down-regulated as marrow cells leave the CD34 + compartment. 18 
Immunohistochemical staining of leukemic blasts
To confirm that both proteins were co-expressed in leukemic cells, replicate blood and marrow smears from selected samples were stained with specific antibodies against HOXA9 and MEIS1. Moderate to high levels of HOXA9 protein, localized primarily in the cytoplasm (black arrows) but also in a speckled pattern over the nucleus (white arrows in insert), were seen in the leukemic blasts from most cases of AML (see panels a and c, Figure 3 and Table 2 ), but not in the lymphoblasts of two cases of ALL (panel e, Figure 3 ) or in one sample of promyelocytic leukemia with the classic t(15;17) translocation (data not shown). Weak to moderate MEIS1 staining was demonstrable in blasts of most of the same myeloid leukemia samples that showed positive signals for HOXA9. MEIS1 protein showed both nuclear (white arrows in insert of panel b, Figure 3 ) and cytoplasmic localization (black arrows in panel d, Figure 3) , and was not demonstrable in two ALL samples (see panel f, Figure 3 ) or one promyelocytic leukemia (not shown). This pattern of cytoplasmic and speckled nuclear staining is reminiscent of that seen with HOXA9 and MEIS1 in myeloid leukemic cell lines.
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Discussion
In this survey, we find that co-activation of HOXA9 and MEIS1 occurs exclusively in AML and is a common event in those cases. This work has been confirmed by one study showing expression of HOXA9 in a smaller series of AML samples, 20 and another study which demonstrated MEIS1 expression in 50% of cases of AML and rarely in ALL. 21 Our study also demonstrates that HOXA9 and MEIS1 proteins are present in leukemic myeloblasts, both in the cytoplasm and the nucleus. We have recently demonstrated, that in myeloid leukemic cell . Note strong and predominantly cytoplasmic HOXA9 staining with weaker speckled nuclear signals (white arrows in insert) for the myeloblasts in patients with AML (panels a and c). MEIS1 staining is weaker and more clearly localized to nuclear speckles (white arrows in insert) with fainter cytoplasmic staining (black arrows) in the same samples (panels b and d). The ALL sample stains for neither protein (panels e and f).
lines, there is significant co-localization of these two proteins by confocal microscopy. 19 The Meis1 gene was initially discovered as a common site of retroviral insertions in myeloid leukemias of BXH-2 mice. 11 The subsequent discovery that activating insertions adjacent to the Hoxa9 and Hoxa7 genes often occurred in the same BXH-2 leukemic cells suggested that Hox and Meis genes could operate in concert to produce murine myeloid leukemias. 12 The MEIS1 gene belongs to the TALE subfamily of non-HOX homeobox genes, characterized by a unique 3-amino acid insert. Other members of the TALE family include the PBX genes, one member of which is involved in the t(1;19) translocation found in pre-B ALL. 22, 23 There are two other known members of the murine MEIS subfamily, Meis2 and Meis3, and in a number of BXH-2-related murine leukemias in which Meis1 is inactive, both Meis2 and Meis3 are expressed. 24 A preliminary report indicates that MEIS2 is also active in human myeloid cell lines. 21 Thus it seems likely that activation of MEIS genes together with HOXA9 and HOXA10 occur in the large majority of cases of AML, with the exception of promyelocytic leukemia.
The uniform lack of expression of HOXA9, HOXA10 and Smears of peripheral blood and/or bone marrow from patients with various FAB subtypes of myeloid leukemia were stained as described in Materials and methods and as depicted in Figure 3 . Intensity of staining of leukemic blasts was assessed semiquantitatively on a scale from 0 to 4+, with 4+ representing the staining intensity of U937 cells, which show high levels of both proteins. Lymphocytes on the smears were consistently negative for both HOXA9 and MEIS1. Furthermore, negative control slides, for which the primary antibody was omitted, showed no staining.
MEIS1 in the FAB-M3 subtype of AML is intriguing and unexplained. It is possible that the malignant promyelocytes, which are typically CD34 − , are beyond the developmental stage at which these genes are normally expressed in blood cells. 25 Given that retinoic acid receptors appear to regulate the activation of HOX genes, 26 it is conceivable that the PML-RAR␣ fusion protein suppresses the expression of these genes. 27 Both HOXA9 and MEIS1 are strongly expressed in all the secondary AMLs tested, including cases progressing from a previous myelodysplastic disorder. The expression of HOXA9 in secondary leukemias is of interest since most of these cases demonstrated loss of one copy of chromosome 7, the site of the HOXA cluster, indicating that the remaining allele remains active. The weak expression of MEIS1 relative to HOXA9 in myelodysplasias suggests that, in these preleukemic disorders, the progression to AML may be a sequential process with initial activation of HOXA9 and then later MEIS1. The low level of activation of MEIS1 in any phase of CML may indicate that MEIS1 is not involved in the induction of that disorder or its progression.
The fact that HOXA and MEIS1 genes are expressed in myeloid leukemias could simply reflect the normal expression of these genes in primitive myeloid cells. Evidence against this hypothesis comes from recent studies comparing the expression of HOXA9, HOXA10 and MEIS1 in sorted CD34 + and CD34
− populations from normal and leukemic human bone marrow. Both HOXA9 and HOXA10 were noted to be sharply down-regulated when normal hematopoietic cells leave the CD34 + compartment. In contrast, in myeloid leukemias, both HOX genes as well as MEIS1 remain activated in the CD34 − population, 21 strongly supporting the notion that the developmental regulation of HOX and MEIS genes in myeloid leukemic cells is perturbed.
The frequent retroviral activation of Hoxa-9 and Meis1 in BXH-2 murine leukemias strongly suggests that there is a biologic interaction between the two genes. Direct evidence for this interaction comes from recent experiments in which mice transplanted with FDCP1 cells engineered to over-express both HOXA9 and MEIS1 all succumbed to a fatal acute myeloid leukemia in less than 2 weeks. 13 In experiments utilizing normal murine marrow over-expressing both genes, leukemia arose in all the transplanted animals in 2 months. In contrast, mice transplanted with cells expressing either HOXA9 or MEIS1 alone, or HOXA9 together with PBX1a, developed leukemias much more slowly or not at all. The rapidity and frequency of leukemias in this model suggests that co-activation of HOXA9 and MEIS1 is sufficient to induce malignant transformation, and may require no other genetic events.
There is now substantial genetic and biochemical evidence that the actions of HOX proteins are mediated by interactions with the non-HOX homeodomain proteins, PBX and MEIS. A large amount of data indicates that HOX proteins from paralog groups 1-10, including HOXA9 and HOXA10, show cooperative DNA binding with the PBX proteins. [28] [29] [30] [31] [32] In a similar fashion, we have recently demonstrated that HOXA9 and HOXA10 proteins can physically interact with the MEIS1 protein, and that these proteins can cooperatively bind DNA on a TGACAGT(T/A)A(T/C)GAC consensus site, in which the TGACAG site is bound by MEIS1.
14 Interestingly only those proteins encoded by the more 5Ј HOX genes, the so-called AbdB members from paralog groups 9-13, can interact with MEIS1. Thus among the 39 HOX proteins only those from paralog groups 9 and 10, including HOXA9 and HOXA10, can interact with both PBX and MEIS1. Since HOXA9 and HOXA10 appear to be the only paralog 9 and 10 genes expressed in blood cells, these two genes may be uniquely positioned as potential oncogenes in myeloid cells. Key issues include determining the identity of downstream target genes that are controlled through such regulatory elements, the possible competition between MEIS1 and PBX proteins for binding with HOXA9 and HOXA10, and regulation of the sub-cellular localization of these proteins.
AML is characterized by a large array of somatic mutations, no one of which occurs in a majority of cases; these findings indicate that no single genetic event triggers AML (reviewed in Ref. 33) . Although the samples used in this study were not directly tested for mutations in either the HOXA9 or MEIS1 genes, we believe it is unlikely that either gene is frequently mutated in human AML. If this supposition is correct, the coactivation of HOXA9 and/or HOXA10 along with MEIS1 in AML must be a common downstream event which accompanies oncogenic mutations in other genes. Examples of such mutations include translocations involving the MLL gene on chromosome 11q. Genetic and molecular biologic evidence strongly indicates that the MLL gene product directly binds to regulatory regions within HOX gene clusters and maintains those genes in an activated configuration. 34, 35 It is noteworthy that we found activation of HOXA9 in samples of leukemias involving 11q translocations. It has been proposed that many other mutations in AML involve genes which encode transcription factors such as retinoic acid receptor alpha (RAR␣) and AML-1, which may perturb the expression and/or function of HOX genes. 33 If this model is correct, therapies designed to disrupt the interactions between HOX and MEIS proteins and their DNA targets could have a therapeutic impact in myeloid leukemias. study, and to Stephen Fong for his capable technical assistance. This work was supported in part by grants from the National Institutes of Health (No. DK48642 to HJL; and No. CA80029 to CL) and by grants from the Department of Veterans Affairs (HJL and CL). HJL is a recipient of a VA Career Development Award.
